Short-term safety assessment in the use of intravenous zoledronic acid in children.
The clinical side effects of the potent new bisphosphonate zoledronic acid in children are unknown. In this study of 34 children with various bone disorders, the frequency of postinfusion flu-like illness, hypocalcemia, and hypophosphatemia was 85%, 74%, and 82%, respectively. No renal side effects were detected after up to 3 consecutive infusions.
Högler
Wolfgang
W
Institute of Endocrinology and Diabetes, Department of Orthopedics, The Children's Hospital of Westmead, Sydney, Australia.
Yap
Fabian
F
Little
David
D
Ambler
Geoffrey
G
McQuade
Mary
M
Cowell
Christopher T
CT
D000293:Adolescent; D001862:Bone Resorption / Q000378:metabolism* / Q000517:prevention & control; D002118:Calcium / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005334:Fever / Q000139:chemically induced; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007262:Infusions, Intravenous; D008297:Male; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D010758:Phosphorus / Q000097:blood; D012189:Retrospective Studies; D013997:Time Factors; D014508:Urea / Q000097:blood; D014839:Vomiting / Q000139:chemically induced; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D010758:Phosphorus; D000077211:Zoledronic Acid; D014508:Urea; D003404:Creatinine; D002118:Calcium